-
1 Comment
Pfenex Inc is currently in a long term uptrend where the price is trading 30.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.4.
Based on the above factors, Pfenex Inc gets an overall score of 2/5.
| ISIN | US7170711045 |
|---|---|
| Sector | Healthcare |
| CurrencyCode | USD |
| Exchange | NYSE MKT |
| Industry | Biotechnology |
| Beta | 1.32 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 13 |
| PE Ratio | 268.67 |
| Market Cap | 437M |
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. As of September 29, 2020, Pfenex Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PFNX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
